XML 49 R34.htm IDEA: XBRL DOCUMENT
v3.25.0.1

REVENUES (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Revenue from Contract with Customer [Abstract] |
Summary of Disaggregation of Revenue | The following table summarizes our Total revenues:
|  | Year Ended December 31, 2024 |  | Year Ended December 31, 2023 |  | Year Ended December 31, 2022 |  |  |  |
(in millions) |  | U.S. |  | Europe(6) |  | Rest of World(6) |  | Total |  | U.S. |  | Europe(6) |  | Rest of World(6) |  | Total |  | U.S. |  | Europe(6) |  | Rest of World(6) |  | Total |  |  |  |
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 10,855 |  |  | $ | 1,509 |  |  | $ | 1,060 |  |  | $ | 13,423 |  |  | $ | 9,692 |  |  | $ | 1,253 |  |  | $ | 905 |  |  | $ | 11,850 |  |  | $ | 8,510 |  |  | $ | 1,103 |  |  | $ | 777 |  |  | $ | 10,390 |  |  |  |  |
Descovy |  | 1,902 |  |  | 100 |  |  | 110 |  |  | 2,113 |  |  | 1,771 |  |  | 100 |  |  | 114 |  |  | 1,985 |  |  | 1,631 |  |  | 118 |  |  | 123 |  |  | 1,872 |  |  |  |  |
Genvoya |  | 1,498 |  |  | 180 |  |  | 84 |  |  | 1,762 |  |  | 1,752 |  |  | 205 |  |  | 103 |  |  | 2,060 |  |  | 1,983 |  |  | 284 |  |  | 136 |  |  | 2,404 |  |  |  |  |
Odefsey |  | 957 |  |  | 290 |  |  | 41 |  |  | 1,288 |  |  | 1,012 |  |  | 294 |  |  | 44 |  |  | 1,350 |  |  | 1,058 |  |  | 364 |  |  | 47 |  |  | 1,469 |  |  |  |  |
Symtuza - Revenue share(1) |  | 450 |  |  | 130 |  |  | 12 |  |  | 592 |  |  | 382 |  |  | 133 |  |  | 13 |  |  | 529 |  |  | 348 |  |  | 168 |  |  | 14 |  |  | 530 |  |  |  |  |
Other HIV(2) |  | 257 |  |  | 129 |  |  | 48 |  |  | 434 |  |  | 238 |  |  | 116 |  |  | 47 |  |  | 401 |  |  | 290 |  |  | 182 |  |  | 59 |  |  | 530 |  |  |  |  |
Total HIV |  | 15,918 |  |  | 2,339 |  |  | 1,355 |  |  | 19,612 |  |  | 14,848 |  |  | 2,102 |  |  | 1,226 |  |  | 18,175 |  |  | 13,820 |  |  | 2,219 |  |  | 1,155 |  |  | 17,194 |  |  |  |  |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sofosbuvir/Velpatasvir(3) |  | 922 |  |  | 299 |  |  | 374 |  |  | 1,596 |  |  | 859 |  |  | 323 |  |  | 355 |  |  | 1,537 |  |  | 844 |  |  | 355 |  |  | 331 |  |  | 1,530 |  |  |  |  |
Vemlidy |  | 486 |  |  | 44 |  |  | 428 |  |  | 959 |  |  | 410 |  |  | 38 |  |  | 414 |  |  | 862 |  |  | 429 |  |  | 35 |  |  | 379 |  |  | 842 |  |  |  |  |
Other Liver Disease(4) |  | 192 |  |  | 202 |  |  | 73 |  |  | 467 |  |  | 152 |  |  | 150 |  |  | 83 |  |  | 385 |  |  | 167 |  |  | 135 |  |  | 124 |  |  | 426 |  |  |  |  |
Total Liver Disease |  | 1,601 |  |  | 545 |  |  | 876 |  |  | 3,021 |  |  | 1,421 |  |  | 511 |  |  | 852 |  |  | 2,784 |  |  | 1,440 |  |  | 525 |  |  | 833 |  |  | 2,798 |  |  |  |  |
Veklury |  | 892 |  |  | 284 |  |  | 623 |  |  | 1,799 |  |  | 972 |  |  | 408 |  |  | 805 |  |  | 2,184 |  |  | 1,575 |  |  | 702 |  |  | 1,628 |  |  | 3,905 |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 234 |  |  | 138 |  |  | 31 |  |  | 403 |  |  | 245 |  |  | 110 |  |  | 15 |  |  | 370 |  |  | 221 |  |  | 75 |  |  | 3 |  |  | 299 |  |  |  |  |
Yescarta |  | 662 |  |  | 666 |  |  | 242 |  |  | 1,570 |  |  | 811 |  |  | 547 |  |  | 140 |  |  | 1,498 |  |  | 747 |  |  | 355 |  |  | 57 |  |  | 1,160 |  |  |  |  |
Total Cell Therapy |  | 896 |  |  | 804 |  |  | 274 |  |  | 1,973 |  |  | 1,055 |  |  | 658 |  |  | 156 |  |  | 1,869 |  |  | 968 |  |  | 430 |  |  | 60 |  |  | 1,459 |  |  |  |  |
Trodelvy |  | 902 |  |  | 294 |  |  | 119 |  |  | 1,315 |  |  | 777 |  |  | 217 |  |  | 68 |  |  | 1,063 |  |  | 525 |  |  | 143 |  |  | 12 |  |  | 680 |  |  |  |  |
Total Oncology |  | 1,798 |  |  | 1,098 |  |  | 393 |  |  | 3,289 |  |  | 1,833 |  |  | 875 |  |  | 224 |  |  | 2,932 |  |  | 1,494 |  |  | 573 |  |  | 73 |  |  | 2,139 |  |  |  |  |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 44 |  |  | 276 |  |  | 212 |  |  | 533 |  |  | 43 |  |  | 260 |  |  | 189 |  |  | 492 |  |  | 57 |  |  | 258 |  |  | 182 |  |  | 497 |  |  |  |  |
Other(5) |  | 255 |  |  | 34 |  |  | 68 |  |  | 356 |  |  | 261 |  |  | 40 |  |  | 66 |  |  | 367 |  |  | 331 |  |  | 65 |  |  | 53 |  |  | 449 |  |  |  |  |
Total Other |  | 299 |  |  | 310 |  |  | 280 |  |  | 889 |  |  | 304 |  |  | 301 |  |  | 255 |  |  | 859 |  |  | 388 |  |  | 323 |  |  | 235 |  |  | 946 |  |  |  |  |
Total product sales |  | 20,508 |  |  | 4,576 |  |  | 3,526 |  |  | 28,610 |  |  | 19,377 |  |  | 4,197 |  |  | 3,361 |  |  | 26,934 |  |  | 18,716 |  |  | 4,342 |  |  | 3,924 |  |  | 26,982 |  |  |  |  |
Royalty, contract and other revenues |  | 82 |  |  | 58 |  |  | 4 |  |  | 144 |  |  | 62 |  |  | 114 |  |  | 7 |  |  | 182 |  |  | 168 |  |  | 127 |  |  | 4 |  |  | 299 |  |  |  |  |
Total revenues |  | $ | 20,591 |  |  | $ | 4,634 |  |  | $ | 3,529 |  |  | $ | 28,754 |  |  | $ | 19,438 |  |  | $ | 4,310 |  |  | $ | 3,368 |  |  | $ | 27,116 |  |  | $ | 18,884 |  |  | $ | 4,469 |  |  | $ | 3,928 |  |  | $ | 27,281 |  |  |  |  |
_______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). See Note 7. Collaborations and Other Arrangements for additional information. (2) Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost. (3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”). (4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi, Sovaldi, Viread and Vosevi. (5) Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig. (6) All individual international locations accounted for less than 10% of Total revenues
Summary of Revenues from Major Customers | The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:
|  | Year Ended December 31,
(as a percentage of total revenues) |  | 2024 |  | 2023 |  | 2022
Cardinal Health, Inc. |  | 26 | % |  | 26 | % |  | 25 | %
Cencora, Inc. |  | 18 | % |  | 19 | % |  | 18 | %
McKesson Corporation |  | 20 | % |  | 21 | % |  | 20 | %
Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods | The following table summarizes revenues recognized from performance obligations satisfied in prior years:
|  | Year Ended December 31,
(in millions) |  | 2024 |  | 2023 |  | 2022
Revenue share with Janssen(1) and royalties for licenses of intellectual property |  | $ | 727 |  |  | $ | 680 |  |  | $ | 783 |
Changes in estimates |  | $ | 452 |  |  | $ | 340 |  |  | $ | 582 |
_______________________________ (1) See Note 7. Collaborations and Other Arrangements for additional information.
Summary of Contract Balances | The following table summarizes our contract balances:
|  | December 31,
(in millions) |  | 2024 |  | 2023
Contract assets |  | $ | 277 |  |  | $ | 117 |
Contract liabilities(1) |  | $ | 58 |  |  | $ | 109 |
_______________________________ (1) Future revenues recognized from contract liabilities are not expected to be material in any one year.

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. + References No definition available. + Details
Name: | us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration